Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Net Margin (2018 - 2025)

10x Genomics' Net Margin history spans 8 years, with the latest figure at 9.79% for Q4 2025.

  • For Q4 2025, Net Margin rose 1992.0% year-over-year to 9.79%; the TTM value through Dec 2025 reached 6.77%, up 2313.0%, while the annual FY2025 figure was 6.77%, 2313.0% up from the prior year.
  • Net Margin for Q4 2025 was 9.79% at 10x Genomics, up from 18.44% in the prior quarter.
  • Across five years, Net Margin topped out at 19.97% in Q2 2025 and bottomed at 60.52% in Q3 2023.
  • The 5-year median for Net Margin is 24.16% (2024), against an average of 25.09%.
  • The largest annual shift saw Net Margin soared 35747bps in 2021 before it crashed -4670bps in 2022.
  • A 5-year view of Net Margin shows it stood at 12.85% in 2021, then grew by 14bps to 11.02% in 2022, then tumbled by -141bps to 26.61% in 2023, then fell by -12bps to 29.71% in 2024, then skyrocketed by 67bps to 9.79% in 2025.
  • Per Business Quant, the three most recent readings for TXG's Net Margin are 9.79% (Q4 2025), 18.44% (Q3 2025), and 19.97% (Q2 2025).